The ribosomal s6 kinases (RSKs) are a family of Ser/Thr kinases, which are downstream effectors of the extracellular signal-regulated kinase 1/2 pathways.^[@ref1]^ RSK appears to be involved in the etiology of a number of different cancers and, importantly, regulates a motility/invasive gene program.^[@ref2]^ RSK is a dual kinase domain protein with the N-terminal kinase domain (NTKD) responsible for phosphorylation of target substrates.^[@ref3]^ In a screen of botanical extracts SL0101 (**1**), a flavonoid glycoside, was identified as an inhibitor of the NTKD of RSK.^[@ref4]^ SL0101 (**1**) is a relatively selective inhibitor for RSK with a *K*~i~ of ∼1 μM. From the crystal structure of SL0101 (**1**) complexed with the NTKD isoform of RSK2^[@ref5]^ and de novo synthetic studies,^[@ref6]^ we identified analogues (**2** and **3**) with C6″-substitutions of the rhamnose that showed improved efficacy in the *in vitro* kinase assays.^[@ref7],[@ref8]^

SL0101 (**1**) has a short biological half-life *in vivo*,^[@ref7]^ which is presumably due to hydrolysis of the C3″/C4″-acetates which are necessary for high affinity.^[@ref9]^ To identify less labile groups that could replace the ester without loss of affinity, we investigated replacing the C4″-acetate with a C4″-acetamide in combination with the C6″-alkyl substitution that we previously identified.^[@ref7]^ Specifically, we targeted six C4″-acetamide analogues **4a**--**d** and **5a**--**b** (Figure [1](#fig1){ref-type="fig"}).

![C4″-amide analogues of SL0101.](ol-2014-03012k_0002){#fig1}

Retrosynthetically, we envisioned that C4″-acetamide substituted analogues **6** could arise from C4″-azido sugar **7a**, which could be prepared from enone sugar **7c** via allylic carbonate **7b** (Scheme [1](#sch1){ref-type="scheme"}). Previously we have shown that C4 allylic azides such as **7a** could be prepared from C4 allylic carbonates like **7b** via Pd-catalyzed allylic alkylation.^[@ref10]^ However, this approach was not compatible for pyran rings with a C1 kaempferol group. To address this issue, a Pd-glycosylation method was developed for the direct incorporation of a C4 azido sugar.

![Retrosynthesis of C4″-Amide SL0101 Analogues](ol-2014-03012k_0004){#sch1}

Our synthesis started with exposure of flavonol **9** and Boc-pyranone **13** to our typical glycosylation conditions (2.5 mol % Pd~2~(DBA)~3~·CHCl~3~ and 10 mol % of PPh~3~ in CH~2~Cl~2~ at 0 °C; 95%), which produced glycosylated pyranone **14** with complete α-selectivity (Scheme [2](#sch2){ref-type="scheme"}). Reduction of the enone **14** (NaBH~4~/CeCl~3~, −78 °C in CH~2~Cl~2~/MeOH; 72%) resulted stereoselectively in allylic alcohol **15**.^[@ref6]^ A methyl carbonate leaving group was installed on the allylic alcohol by reaction of **15** with methyl chloroformate to form the C4″-carbonate **16** in 75% yield. Unfortunately, exposure of carbonate **16** to the Sinou conditions (TMSN~3~, \[Pd(allyl)Cl\]~2~/1,4-bis(diphenylphosphino)butane) failed to afford the desired regio- and stereoisomeric allylic azide **17**. The C-1 kaempferol proved to be the better leaving group, as only products consistent with the hydrolysis at the anomeric position were observed.^[@ref11]^

![Unsuccessful Approach to C4″-Azide Sugar **17**](ol-2014-03012k_0005){#sch2}

To solve this problem, we decided to try reversing the sequence of the two Pd-π-allyl substitution reactions, which required the synthesis of allylic azides **29** and **30** (Scheme [3](#sch3){ref-type="scheme"}). This began with a palladium-catalyzed glycosylation (Pd(0)/PPh~3~, 1:2) of *p*-methoxybenzyl alcohol with Boc-pyranones **13** and **18** which stereoselectively afforded PMB-pyranones **19** and **20** (95% and 92% respectively). Diastereoselective reduction of the two enones (NaBH~4~/CeCl~3~, −78 °C in CH~2~Cl~2~/MeOH; 92% and 84%) gave allylic alcohols **21** and **22**. Treatment of the two allylic alcohols with methyl chloroformate in the presence of a catalytic amount of DMAP gave the allylic carbonates **23** and **24** (94% and 90%). Exposure of the carbonates to the Sinou conditions (TMSN~3~, \[Pd(allyl)Cl\]~2~/1,4-bis(diphenylphosphino)butane) regio- and stereospecifically afforded the desired allylic azides **25** and **26** (73% and 75%). An oxidative PMB deprotection (DDQ/H~2~O) of **25** and **26** provided anomeric alcohols **27** and **28** as a 13:1 mixture of anomers in 73% and 78% yields. The following Boc-protection of the two alcohols produced the key azido containing intermediates **29** and **30** in 84% and 82% yields with excellent diastereoselectivity.

![Synthesis of C4″-Azide Sugar Glycosyl Donors **29**/**30**](ol-2014-03012k_0006){#sch3}

To our delight, exposure of sugar donor Boc-allylic azides **29** and **30** and acceptor **9** to our typical Pd-catalyzed glycosylation conditions provided our desired glycosylated allylic azides **17** and **31** in excellent yield (98% and 90%) with complete α-selectivity and no sign of hydrolysis at the anomeric position. Exposure of the two allylic azides to Upjohn conditions (OsO~4~/NMO; 91% and 87%) stereoselectively converted them into the two rhamno-diols **32** and **33**, which are poised for further manipulation into the desired SL0101 analogues (Scheme [4](#sch4){ref-type="scheme"}).

![Synthesis of C4″-Azido Rhamno-sugars **32**/**33**](ol-2014-03012k_0007){#sch4}

We next investigated the reduction and acylation of azidodiols **32** and **33** (Scheme [5](#sch5){ref-type="scheme"}).^[@ref6]^ Fortuitously, both the C4 acylated amides **36** and **37** and C3/C4 bis-acylated products **34** and **35** were generated in an ∼1:1 mixture in one pot from the reduction of **32** and **33** with zinc dust in the presence of acetic anhydride and acetic acid. Thus, the reduction acylatio*n* of **32** gave the desired C4″-acetamides **36** (29%) and **34** (27%), whereas the reduction acylation of **33** gave the desired C4″-acetamides **37** (36%) and **35** (32%).

![Synthesis of C4″-Amide Analogues of SL0101 (**4**/**5**)](ol-2014-03012k_0008){#sch5}

The intermediates **34**--**37** were globally deprotected by an exhaustive hydrogenolysis, which produced four of the desired analogues. Thus, exposure of **34** and **35** to typical hydrogenolysis conditions (1 atm of hydrogen with Pd/C) furnished **4b** and **5b** in good yields (86% and 88%, respectively). Exposure of **36** and **37** to similar hydrogenolysis conditions furnished **4a** and **5a** in good yields (90% and 86%, respectively). Finally the last two analogues **4c** and **4d** were prepared by an acylation deprotection sequence. The peracylated product **4d** was prepared from **34** in 91% overall yield by bis-acylation (Ac~2~O, DMAP/Py; 97%) and exhaustive hydrogenolysis. Similarly, the C2 acylated product **4c** was prepared from **36** via an ortho-ester mediated C2-acylation (CH~3~C(OMe)~3~, 10% *p*-TsOH in CH~2~Cl~2~; then excess 90% AcOH/H~2~O; 85%) and per-hydrogenolysis (94% overall yield).

The efficacy of the analogues **4a**--**d** and **5a**--**b** to inhibit RSK2 activity was determined in an *in vitro* kinase assay using purified recombinant RSK2 (Table [1](#tbl1){ref-type="other"}).^[@ref4]^ The data were fit using nonlinear regression analysis. In the *n*-Pr series, **4b** and **4c** with a single acetate at the C3″- or C2″-position had significantly lower (∼5-fold) IC~50~'s compared to SL0101. However, when compared with our best analogue **2a** (C3″/C4″-diacetate, Figure [1](#fig1){ref-type="fig"}) the related C4″-acetamide **4b** had a 10-fold increase in IC~50~.^[@ref7]^ The IC~50~'s for **4a** with no C2″- or C3″-acetate and **4d** with two acetates were not statistically different from that of SL0101. These results are similar to those obtained in the series in which the acetyl group was at the C4″-position.^[@ref7]^ In the isobutyl series the C3″-acetate **5b** had a 3-fold improved IC~50~ compared to that of SL0101, whereas **5a** with no C2″- or C3″-acetate had a much poorer IC~50~ than SL0101. This suggests that, in the *n*-Pr-series, the C4″-acetamide can replace the C4″-acetate without dramatically compromising the affinity of the analogues for RSK2.

###### *In Vitro* Potency of SL0101 (**1**) and Analogues[a](#t1fn1){ref-type="table-fn"}

  compd name       RSK2 IC~50~ \[μM\]   RSK2 IC~50~*p*(**1**)   MCF-7 proliferation \[% control\]   MCF-7 proliferation *p*(DMSO)   MCF-7 proliferation *p*(**1**)
  ---------------- -------------------- ----------------------- ----------------------------------- ------------------------------- --------------------------------
  SL0101 (**1**)   1.04 ± 0.60                                  38.6 ± 14.6                         \<0.01                           
  **4a**           0.76 ± 0.43          0.17                    94.5 ± 21.6                         0.41                             
  **4b**           0.23 ± 0.07          \<0.01                  39.2 ± 7.2                          \<0.01                          0.91
  **4c**           0.11 ± 0.09          \<0.01                  47.8 ± 10.6                         \<0.01                          0.16
  **4d**           0.44 ± 0.39          0.02                    --80.0 ± 6.6                        \<0.01                          \<0.01
  **5a**           2.33 ± 0.88          \<0.01                  47.5 ± 19.1                         \<0.01                          0.21
  **5b**           0.32 ± 0.18          \<0.01                  24.6 ± 10.4                         \<0.01                          0.03

RSK2 IC~50~: concentration needed for 50% RSK2 inhibition (*n* \> 2; quadruplicate: mean, S.D.; *p*(**1**) Student's *t* test compared to SL0101(**1**)). MCF-7 proliferation: (*n* \> 2; triplicate: mean, S.D.; *p*(DMSO) Student's *t* test compared to control; *p*(**1**) Student's *t* test compared to SL0101 (**1**)). *p* \< 0.01 significant.

The six analogues were evaluated for their ability to decrease proliferation of the breast cancer cell line, MCF-7 (Table [1](#tbl1){ref-type="other"}). Initially, each analogue was tested at a dose of 100 μM and compared to SL0101 (**1**). Analogue **4d** was the only analogue that inhibited proliferation to a greater extent than SL0101 (**1**). A dose response curve with **4d** showed that cytostasis occurred at ∼35 μM and substantial cell death occurred at ∼50 μM (see [Suppporting Information](#notes-2){ref-type="notes"} (SI)). For comparison SL0101 (**1**) at 100 μM (maximum concentration) induces a reduction in proliferation (∼60%). To evaluate whether **4d** was specific for RSK, we compared its antiproliferative effects in MCF-7 cells versus MCF-10A, an immortalized nontransformed human breast cell line. We previously found that a preferential ability to inhibit MCF-7 compared to MCF-10A proliferation correlates with specificity for RSK inhibition.^[@ref4],[@ref7]−[@ref12]^ At 25 μM **4d** inhibited proliferation of MCF-7 cells by 50% and mariginally inhibited MCF-10A proliferation (see [SI](#notes-2){ref-type="notes"}). However, at 50 μM of **4d**, a cytotoxic dose in MCF-7 cells, proliferation of MCF-10A cells was inhibited by 70%. Thus, **4d** shows a very limited ability to preferentially inhibit MCF-7 proliferation and survival compared to MCF-10A cells. These results suggest that **4d** is not a specific RSK inhibitor in intact cells.

To further evaluate the specificity of **4d** at inhibiting RSK, we compared the efficacy of SL0101 (**1**) and **4d** to alter the phosphorylation of known RSK substrates. We chose to test **4d** at both cytostatic (25 μM) and cytotoxic (50 μM) concentrations. To increase the phosphorylation of substrates MCF-7 cells were stimulated with the mitogen, phorbol myristate acetate (PMA), after a pretreatment with inhibitor or vehicle. RSK phosphorylates and inhibits the activity of eukaryotic elongation factor 2 (eEF2) kinase.^[@ref13]^ Thus, inhibition of RSK relieves the inhibition of eEF2 kinase, which results in an increase in p-eEF2. As expected activation of RSK by PMA led to a decrease in p-eEF2 and inhibition of RSK with SL0101 increased p-eEF2 compared to the PMA control (Figure [2](#fig2){ref-type="fig"}).

![RSK biomarkers comparison of **4d** and **1**. Comparison of analogue **4d** and SL0101 (**1**) was made against known RSK biomarkers in intact cells. MCF-7 cells were pretreated with **4d** at the indicated concentrations and then treated with vehicle or PMA. Lysates were analyzed by immunoblotting. The motif, (K/R)x(K/R)xx(pS/pT), is recognized by a number of kinases, including RSK. The arrows indicate bands whose intensity is altered upon treatment of cells with SL0101 (**1**).](ol-2014-03012k_0003){#fig2}

Ribosomal protein S6, a component of the 40S ribosomal subunit, is phosphorylated by RSK,^[@ref14]^ and in agreement with these data SL0101 (**1**) inhibits PMA-induced phosphorylation of S6. We have also found that RSK regulates the levels of the oncogene, cyclin D1, in MCF-7 cells.^[@ref15]^ Consistent with these observations SL0101 (**1**) inhibited cyclin D1 levels. In contrast with our observations with SL0101 the analogue **4d** did not alter the phosphorylation status of eEF2, S6 or the levels of cyclin D1. To further investigate the ability of **4d** to inhibit RSK in intact cells, we immunoblotted the lysates with an antibody against the phosphorylation motif that is recognized by numerous kinases, including RSK. Treatment with SL0101 increased the phosphorylation of a band at ∼60 kDa and decreased the intensity of a band at ∼27 kDa. Analogue **4d** did not alter the phosphorylation pattern as compared to PMA. Consistent with these results we observed that analogue **4b** (100 μM) did not alter the phosphorylation of RSK biomarkers or cyclin D1 levels in intact cells (data not shown). These results suggest that the amide analogues of SL0101 (**1**) are not specific for RSK.

In conclusion, using de novo synthesis C4″-acetamide analogues of SL0101 with a C6″ substitution were prepared and evaluated as RSK inhibitors. Analogues with improved *in vitro* kinase inhibitory activities were identified; however, this increase in activity came at a loss of selectivity for RSK. Further studies aimed at defining the requirements for a specific-RSK inhibition are ongoing and will be reported in due course.

Experimental procedures and spectral data for all new compounds. This material is available free of charge via the Internet at <http://pubs.acs.org>.
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